Jenna Gregory

Last updated
Jenna Mair Gregory
FRCPath
Professor Jenna Gregory.jpg
Born (1984-01-22) January 22, 1984 (age 41)
Stockport, England
Alma mater University of St. Andrews (BSc)
University of Cambridge (MBChir, PhD)
University of Edinburgh (MSc, MMedSci)
Scientific career
Fields Neuroscience
Pathology
Molecular pathology
Preventive healthcare
Institutions University of Aberdeen
Thesis Investigating the role of TDP-43 aggregation in the pathogenesis of ALS and FTD-U (2011, University of Cambridge)
Doctoral advisor Sir Christopher Martin Dobson FRS FMedSci FRSC
Additional theses
MSc A systematic approach to identify oral neuroprotective interventions for motor neuron disease (2015, University of Edinburgh)
MMedSci Interrogating the spatial transcriptome of motor neurone disease (2016, University of Edinburgh)
Website Gregory Laboratory

Professor Jenna Gregory (born 22 January 1984) BScMScMMedSciPhDMBChir (Cantab.) FRCPath is a British clinical academic and consultant histopathologist who holds a Clinical Chair at the University of Aberdeen, specializing in neurodegenerative diseases with a focus on early detection and disease prevention. [1] [2] [3] She serves as Clinical Lead for the NHS Grampian Tissue Bank. Jenna’s research investigates the pathomechanisms of ALS-FTSD and other neurodegenerative diseases with a translational focus on combining early detection priorities with precision-medicine principles to empower precision-prevention strategies. [4] [5]

Contents

She is a qualified and internationally established researcher, [2] clinician, [6] clinical trialist, [7] [8] [9] [10] biobanker, [11] biomarker developer, [12] [13] [14] [15] and neuroscience thought leader, [5] holding academic qualification in neuroscience (BSc, PhD), clinical trials (MSc), [7] and molecular pathology (MMedSci) [16] with professional qualifications in medicine (MBChir) and pathology (FRCPath).

Early life and education

Jenna Gregory was born in Stockport, England. [17] She began her medical education at the University of St Andrews in 2003, where she obtained an intercalated BSc in Neuroscience in 2007.

In 2007, Gregory joined the University of Cambridge as part of the MD PhD programme, obtaining her PhD in Chemistry and Medicine in 2011 under the supervision of Chris Dobson [18] FRSFMedSciFRSC.

In 2013, she entered the academic foundation programme at the University of Edinburgh, completing a part-time MSc in Clinical Trials (2013–2016) [7] and a MMedSci in Molecular Pathology (2016–2017) [16] . She began specialist training in pathology in 2017.

In 2018, Gregory established her independent research group as a clinical lecturer at the University of Edinburgh and was awarded a Scottish Clinical Research Excellence Development Scheme (SCREDS) Clinical Lectureship. [19] She later received a Jean Shanks Foundation Grant [1] and a Pathological Society Clinical Lecturer Support Grant. [1]

Gregory moved to University of Aberdeen in 2022, where she established her research group as a Senior Lecturer at the Institute of Medical Sciences. She qualified as a consultant histopathologist (FRCPath) in 2021 and began practicing with NHS Grampian in 2022. [6] She became clinical lead for the NHS Grampian Biorepository/Tissue bank in 2023. [11] She became Clinical Professor at the University of Aberdeen in 2024. [20]

Research and Career

St. Andrews (2003–2007)

As part of an intercalated medical degree at the University of St. Andrews, Jenna obtained a BSc in Neuroscience in 2007 with project thesis supervised by Prof. Jim Aiton working on the chaperone Peroxiredoxin II, entitled “Over-expression of peroxiredoxin II protects cultured SK-N-SH cells from amyloid-beta toxicity”. [1]

Cambridge (2007–2013)

Jenna moved to the University of Cambridge in 2008 as part of the MD PhD programme, working out of the Departments of Genetics and Chemistry, and obtained her PhD in Chemistry and Medicine in 2011 under the supervision of Sir Chris Dobson [18] FRSFMedSciFRSC with thesis entitled “Investigating the role of TDP-43 aggregation in the pathogenesis of ALS and FTD-U”. [1]

As part of her PhD at the University of Cambridge, Jenna created and published one of the first TDP-43 Drosophila melanogaster animal models for preclinical research in amyotrophic lateral sclerosis, [21] and showed that the molecular chaperone Clusterin could also participate in intracellular aggregation events rescuing TDP-43 pathology in a paper [22] that was later published in 2017.

Edinburgh (2013–2022)

Jenna moved to the University of Edinburgh as part of the prestigious academic foundation programme in 2013. Alongside her full-time clinical training on this programme Jenna obtained a part-time MSc in Clinical Trials (2013–2016) with thesis titled, “A systematic approach to identify oral neuroprotective interventions for motor neuron disease”. [7]

As part of her MSc in Clinical Trials, and to inform drug selection for MND SMART (Motor Neuron Disease – Systematic Multi-arm Adaptive Randomised Trial), Jenna undertook a large systematic review and meta-analysis of all published literature in neurodegenerative disease (study protocol published in Evidence-based Preclinical Medicine in 2016). [23] This study included >14,000 human and animal model publications screened for relevance, with data extracted from 396 studies with findings presented in Jenna’s MSc thesis [7] , therein, Jenna identified memantine as the leading drug candidate for oral intervention in MND, leading to the data-driven selection of memantine as one of the first two drugs (along with trazadone) trialled in MND-SMART, [8] which recruited its first patient on 27/02/2020.

In her capacity as a qualified clinical trialist, Jenna contributed to the initial versions of the trial protocol and the ethics submission for MND-SMART, the first adaptive multi-arm clinical trial for a neurodegenerative disease in the world, which in 2018 received a £1.5 million investment from MND Scotland [24] to establish the UK-wide MND-SMART clinical trial, and whose ethics submission was approved by the West of Scotland Research Ethics Committee on 2 October 2019. [25]

Recognising the important contribution of molecular stratification in oncology clinical trials, alongside the relative absence of molecular markers in neurodegeneration, Jenna undertook an MMedSci in Molecular Pathology (2016–2017) with funding from Biogen and the MRC. Jenna went to Karolinska Institute to learn spatial sequencing techniques (later to become 10X sequencing) in the lab of Joakim Lundberg, producing her thesis “Interrogating the spatial transcriptome of motor neurone disease”. [16]

In 2018, Jenna established her independent research group as a clinical lecturer at the University of Edinburgh having been awarded a SCREDS Clinical Lectureship. [19] This was followed in 2019 by a Scottish Universities Life Sciences Alliance (SULSA) Postdoctoral and Early Career Researcher Exchange Scheme (PECRE) award to train at the New York Genome Centre/Columbia University for the project ‘Interrogating the spatial transcriptome of cognition in ALS patients’. [16] In 2020 Jenna was awarded a Jean Shanks Foundation Grant and a Pathological Society Clinical Lecturer Support Grant. [1]

Aberdeen (2022–present)

Jenna moved to Aberdeen in 2022, establishing her research group as a Senior Lecturer at the Institute of Medical Sciences of the University of Aberdeen, with a translational focus on precision-prevention and precision medicine in neurodegenerative diseases. [26]

In 2022 Jenna qualified as a consultant histopathologist (FRCPath) in 2021, [6] and was awarded a Target ALS Early-Stage Clinician Grant. [27] She became the clinical lead for the NHS Grampian Biorepository/Tissue bank in 2023, [11] and became Clinical Professor at the University of Aberdeen in 2024. [20]

Research Themes

Themes in Jenna Gregory’s research in neurodegenerative diseases include:

1. ALS pathomechanisms and protein aggregation [12] [15] [21] [28] [29] [14] [30] [31] [32] [33] [34] [35]

2. Biomarkers and molecular diagnostics [36] [34] [12] [32] [14] [15]

3. Neuroinflammation and immune mechanisms [37] [38]

4. Cognition and brain health [39] [40] [41] [42] [43] [44] [45] [46]

5. Machine learning and AI in neurodegenerative disease research [40] [36] [41] [47] [48]

6. Clinical trials and drug repurposing [7] [9] [23] [8]

7. Spatial transcriptomics [16] [44] [45]

8. Epidemiological studies in ALS [49] [50] [40]

9. Biophysics and structural biology [15] [34]

10. Disease heterogeneity: stratification and precision medicine [37] [34] [41] [47] [45]

11. RNA biology and mRNA localisation [51] [29]

12. ALS genetics and molecular mechanisms [52] [37] [53] [54]

13. Cell energetics, proteostasis, stress and cell phenotypes [55] [21] [56] [54] [57] [58] [59] [48]

14. Resources and methods in histopathology [60] [61] [62]

Selected publications

Spence* H, Waldron* FM, Saleeb RS, Brown AL, Rifai OM, Gilodi M, Read F, Roberts K, Milne G, Wilkinson D, O'Shaughnessy J, Pastore A, Fratta P, Shneider N, Tartaglia GG, Zacco E, Horrocks MH, Gregory JM (2024). RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica 2024 Mar 5;147(1):50. *equal contributions [12]

Balendra R, Sreedharan J, Hallegger M, Luisier R, Lashuel HA, Gregory JM, Patani R (2025). Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy. Lancet Neurology 24(5):456-470 [35]

Cox D, Burke M, Milani S, White MA, Waldron FM, Böken D, Lobanova E, Sreedharan J, Gregory JM, Klenerman D (2025). Quantitative profiling of nanoscopic protein aggregates reveals specific fingerprint of TDP-43-positive assemblies in motor neuron disease. Advanced Science e05484 [34]

Pattle SB, O’Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, Hays N, Arends MJ, Horrocks MH, Waldron FM, Gregory JM (2023). pTDP-43 aggregates accumulate in non-CNS tissues prior to symptom onset in ALS: a case series linking archival surgical biopsies with clinical phenotypic data. Journal of Pathology: Clinical Research 9:44-55. [31]

Funding

Jenna Gregory’s research has been funded by Target ALS [27] [63] [64] , MND Association [65] , LifeArc [5] , National Institutes of Health [66] , MND Scotland [67] , Jean Shanks Foundation, Scottish Universities Life Science Alliance [68] , UKRI/Medical Research Council [69] , MND Scotland and Scottish Government’s Chief Scientist Office [70] [71] , The Royal Society, Chan Zuckerberg Initiative, Pathological Society, Academy of Medical Sciences.

References

  1. 1 2 3 4 5 6 Jenna Gregory ORCID 0000-0003-3337-4079 https://orcid.org/my-orcid?orcid=0000-0003-3337-4079
  2. 1 2 Jenna Gregory’s publications indexed by Google Scholar https://scholar.google.com/citations?user=LI1jAZEAAAAJ&hl=en
  3. ↑ Jenna Gregory’s publications https://gregorylaboratory.com/publications/
  4. ↑ Gregory, J.M. (2024). How can we improve treatment success in MND? - Jenna Gregory | MND Scotland LEARN 2024 https://www.youtube.com/watch?v=kEXcDtMLKTI&t=25s
  5. 1 2 3 Gregory, J.M. (2025). LifeARC podium presentation: Developing novel tools to measure TDP43 in MND. https://www.youtube.com/watch?v=sdQzdCCJUT0
  6. 1 2 3 GMC General Medical Council Specialist Register: Jenna Gregory. https://www.gmc-uk.org/registrants/7414268
  7. 1 2 3 4 5 6 Gregory, J.M. (2016). A systematic approach to identify oral neuroprotective interventions for motor neuron disease. https://figshare.com/articles/thesis/Gregory2016_MSc_Thesis_ClinTrials_UEdinburgh_A_systematic_approach_to_identify_oral_neuroprotective_interventions_for_motor_neuron_disease_pdf/29149673?file=54838550
  8. 1 2 3 Wong, C., Dakin, R.S., Williamson, J., et al. (2022). Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART). BMJ Open 12, e064173.
  9. 1 2 Wong, C., Gregory, J.M., Liao, J., Egan, K., Vesterinen, H.M., Ahmad Khan, A., Anwar, M., Beagan, C., Brown, F.S., Cafferkey, J., et al. (2023). A systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus. BMJ Open 13, e064169.
  10. ↑ Wong, C., Gregory, J.M., Liao, J., Egan, K., Vesterinen, H.M., Khan, A.A., Anwar, M., Beagan, C., Brown, F., Cafferkey, J., et al. (2022). A Systematic Approach to Identify Neuroprotective Interventions for Motor Neuron Disease. medRxiv, 2022.2004.2013.22273823.
  11. 1 2 3 NHS Grampian Biorepository https://www.biorepository.nhsgrampian.org/
  12. 1 2 3 4 Spence, H., Waldron, F.M., Saleeb, R.S., Brown, A.-L., Rifai, O.M., Gilodi, M., Read, F., Roberts, K., Milne, G., Wilkinson, D., et al. (2024). RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica 147, 50.
  13. ↑ Waldron, F.M., Langerová, T., Read, F.L., Spence, H., Hanna, K., Roberts, K., Pattle, S.B., and Gregory, J.M. (2025). Improved detection of pre-symptomatic, non-central nervous system TDP-43 pathology in amyotrophic lateral sclerosis using RNA aptamer. bioRxiv, 2025.2004.2010.648122.
  14. 1 2 3 Zacco, E., Gilodi, M., Armaos, A., Waldron, F.M., Rupert, J., Schneider, N., Gregory, J.M., and Tartaglia, G.G. (2025). Computationally Designed RNA Aptamers Enable Selective Detection of FUS Pathology in ALS. bioRxiv, 2025.2004.2030.651570.
  15. 1 2 3 4 Zacco, E., Kantelberg, O., Milanetti, E., Armaos, A., Panei, F.P., Gregory, J., Jeacock, K., Clarke, D.J., Chandran, S., Ruocco, G., et al. (2022). Probing TDP-43 condensation using an in silico designed aptamer. Nature Communications 13, 3306.
  16. 1 2 3 4 5 Gregory, J.M. (2017). Interrogating the spatial transcriptome of motor neurone disease. MMedSci (University of Edinburgh).https://doi.org/10.6084/m9.figshare.29149670.v1
  17. ↑ Biography - Gregory Lab https://gregorylaboratory.com/biography/
  18. 1 2 Chris Dobson - Wikipedia https://en.wikipedia.org/wiki/Chris_Dobson#cite_ref-cv_2-14
  19. 1 2 SCREDS Clinical Lectureship - Euan MacDonald Centre People https://euanmacdonaldcentre.org/people/dr-jenna-gregory
  20. 1 2 Jenna M Gregory. Clinical Professor at the University of Aberdeen https://www.abdn.ac.uk/people/jenna.gregory
  21. 1 2 3 Gregory, J.M., Barros, T.P., Meehan, S., Dobson, C.M., & Luheshi, L.M. (2012). The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila. PLoS One 7, e31899.
  22. ↑ Gregory, J.M., Whiten, D.R., Brown, R.A., Barros, T.P., et al. (2017). Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropatholica Communications 5, 81.
  23. 1 2 Gregory, J.M., Waldron, F.M., Soane, T., Fulton, L., Leighton, D., Chataway, J., Pal, S., Chandran, S., & Macleod, M.R. (2016). Protocol for a systematic review and meta-analysis of experimental models of amyotrophic lateral sclerosis. Evidence-based Preclinical Medicine 3, e00023.
  24. ↑ MND-SMART (2018). MND Scotland: “Ground-breaking MND drug trial launched” https://mndscotland.org.uk/research/take-part/
  25. ↑ NHS Health Research Authority. MND-SMART: Research Ethics Committee Reference 19/WS/0123. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/mnd-smart/
  26. ↑ Gregory Lab Homepage. https://gregorylaboratory.com/
  27. 1 2 Target ALS. Breakthroughs in Biomarker Research: Insights From Our 2024 Annual Meeting. https://www.targetals.org/2024/06/28/breakthroughs-in-als-biomarker-research/
  28. ↑ Barton SK, Magnani D, James OG, et al. (2021). Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell model. Brain Communications 3:fcab255. https://doi.org/10.1093/braincomms/fcab255
  29. 1 2 Barton SK, Gregory JM, Selvaraj BT, McDade K, Henstridge CM, Spires-Jones TL, et al. (2021). Dysregulation in subcellular localization of myelin basic protein mRNA does not result in altered myelination in ALS. Frontiers in Neuroscience 15:705306. https://doi.org/10.3389/fnins.2021.705306
  30. ↑ Cassel R, Lorenc F, Bombardier A, et al. (2025). FUS mislocalization rewires a cortical gene network to drive cognitive and behavioral impairment in ALS. medRxiv. https://doi.org/10.1101/2025.06.16.25329673
  31. 1 2 Pattle SB, O’Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, Hays N, Arends MJ, Horrocks MH, Waldron FM, Gregory JM. (2023). pTDP-43 aggregates accumulate in non-CNS tissues prior to symptom onset in ALS: a case series linking archival surgical biopsies with clinical phenotypic data. J Pathology: Clinical Research 9:44-55. https://doi.org/10.1002/cjp2.297
  32. 1 2 Waldron FM, Langerová T, Rahmanova A, Read FL, Spence H, Roberts K, MacLeod AD, Pattle SB, Hanna K, Gregory JM. (2025). Skin TDP-43 pathology as a candidate biomarker for predicting ALS decades prior to motor symptom onset. bioRxiv. https://doi.org/10.1101/2025.04.10.648122
  33. ↑ Waldron FM, Spence H, Taso OS, Read FL, Sinha IR, Irwin KE, Wong PC, Ling JP, Gregory JM. (2025). Brain iron as a surrogate biomarker of pathological TDP-43 identifies region-specific signatures in ageing, Alzheimer’s disease and ALS. bioRxiv. https://doi.org/10.1101/2025.10.02.680028
  34. 1 2 3 4 5 Cox D, Burke M, Milani S, White MA, Waldron FM, Böken D, Lobanova E, Sreedharan J, Gregory JM, Klenerman D. (2025). Quantitative profiling of nanoscopic protein aggregates reveals specific fingerprint of TDP-43-positive assemblies in motor neuron disease. Advanced Science e05484. https://doi.org/10.1002/advs.202505484
  35. 1 2 Balendra R, Sreedharan J, Hallegger M, Luisier R, Lashuel HA, Gregory JM, Patani R. (2025). Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy. Lancet Neurology 24(5):456-470. https://doi.org/10.1016/S1474-4422(25)00109-7
  36. 1 2 Majumder V, Gregory JM, Barria MA, Green A, Pal S. (2018). TDP-43 as a potential biomarker for ALS: a systematic review and meta-analysis. BMC Neurology 18:90. https://doi.org/10.1186/s12883-018-1091-7
  37. 1 2 3 Rifai OM, O’Shaughnessy J, Dando OR, et al. (2023). Distinct neuroinflammatory signatures exist across genetic and sporadic ALS cohorts. Brain awad243. https://doi.org/10.1093/brain/awad243
  38. ↑ Banerjee P, Elliott E, Rifai OM, et al. (2022). NLRP3 inflammasome as a key molecular target underlying cognitive resilience in ALS. Journal of Pathology 256:262-268. https://doi.org/10.1002/path.5846
  39. ↑ Johnstone AM, Albanese E, Crabtree DR, et al. (2025). Consensus statement on exploring the nexus between nutrition, brain health and dementia prevention. Nutrition and Metabolism 22:82. https://doi.org/10.1186/s12986-025-00981-6
  40. 1 2 3 Johnson H, Longden J, Cameron G, Waiter GD, Waldron FM, Gregory JM, Spence H. (2025). Machine learning identifies routine blood tests as accurate predictive measures of pollution-dependent poor cognitive function. bioRxiv. https://doi.org/10.1101/2025.01.10.632396
  41. 1 2 3 Xia Y, Gregory JM, Waldron FM, Spence H, Vallejo M. (2024). Integrating transfer learning and attention mechanisms for accurate ALS diagnosis and cognitive impairment detection. medRxiv. https://doi.org/10.1101/2024.09.22.24313406
  42. ↑ Gregory JM, Elliott E, McDade K, Bak T, Pal S, Chandran S, Abrahams S, Smith C. (2020). Neuronal clusterin expression is associated with cognitive protection in ALS. Neuropathology and Applied Neurobiology 46:255-263. https://doi.org/10.1111/nan.12575
  43. ↑ Gregory JM, McDade K, Livesey MR, Croy I, Marion de Proce S, Aitman T, Chandran S, Smith C. (2020). Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in ALS. Neuropathology and Applied Neurobiology 46:441-457. https://doi.org/10.1111/nan.12597
  44. 1 2 Mehta AR, Selvaraj BT, Barton SK, McDade K, Abrahams S, Chandran S, Smith C, Gregory JM. (2020). Improved detection of RNA foci in C9orf72 ALS post-mortem tissue using BaseScope™ shows lack of association with cognitive dysfunction. Brain Communications 2:fcaa009. https://doi.org/10.1093/braincomms/fcaa009
  45. 1 2 3 Petrescu J, Roque CG, Jackson CA, Daly A, Kang K, Casel O, Leung M, Reilly L, Eschbach J, McDade K, et al. (2025). Differential cellular mechanisms underlie language and executive decline in ALS. bioRxiv. https://doi.org/10.1101/2025.02.26.640433
  46. ↑ Rifai OM, Waldron FM, Shaughnessy J, Read FL, Gilodi M, Pastore A, Shneider N, Tartaglia GG, Zacco E, Spence H, Gregory J. (2024). Amygdala TDP-43 pathology is associated with behavioural dysfunction and ferritin accumulation in ALS. bioRxiv https://doi.org/10.1101/2024.06.01.596819
  47. 1 2 Rifai OM, Longden J, O’Shaughnessy J, Sewell MDE, Pate J, McDade K, Daniels MJD, Abrahams S, Chandran S, McColl BW, Gregory JM, et al. (2022). Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72-ALS. Journal of Pathology 258:366-381. https://doi.org/10.1002/path.6008
  48. 1 2 Krispin S, van Zuiden W, Danino YM, Molitor L, Rudberg N, Bar C, Coyne A, Meimoun T, Waldron FM, Gregory JM, et al. (2025). Organellomics: AI-driven deep organellar phenotyping reveals novel ALS mechanisms in human neurons. bioRxiv. https://doi.org/10.1101/2024.01.31.572110
  49. ↑ Elliott E, Newton J, Rewaj P, et al. (2020). An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:116-122. https://doi.org/10.1080/21678421.2019.1672748
  50. ↑ Leighton DJ, Ansari M, Newton J, Parry D, Cleary E, Colville S, Stephenson L, Larraz J, Johnson M, Beswick E, et al. (2023). Genotype–phenotype characterisation of long survivors with motor neuron disease in Scotland. J Neurology. https://doi.org/10.1007/s00415-022-11505-0
  51. ↑ Barton SK, Gregory JM, Chandran S, Turner BJ. (2019). Could an impairment in local translation of mRNAs in glia be contributing to pathogenesis in ALS? Frontiers in Molecular Neuroscience 12:124. https://doi.org/10.3389/fnmol.2019.00124
  52. ↑ Gregory JM, Fagegaltier D, Phatnani H, Harms MB. (2020). Genetics of Amyotrophic Lateral Sclerosis. Current Genetic Medicine Reports 8:121–131. https://doi.org/10.1007/s40142-020-00194-8
  53. ↑ Rifai OM, Waldron FM, Sleibi D, O'Shaughnessy J, Leighton DJ, Gregory JM. (2024). Clinicopathological analysis of NEK1 variants in amyotrophic lateral sclerosis. Brain Pathology e13287. https://doi.org/10.1111/bpa.13287
  54. 1 2 Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, Chouhan AK, Gane AB, Perkins EM, Dando O, et al. (2018). C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nature Communications 9:347. https://doi.org/10.1038/s41467-017-02729-0
  55. ↑ Elliott E, Bailey O, Waldron FM, et al. (2020). Therapeutic targeting of proteostasis in ALS – a systematic review and meta-analysis of preclinical research. Frontiers in Neuroscience 14:511. https://doi.org/10.3389/fnins.2020.00511
  56. ↑ Crippa V, Cicardi ME, Ramesh N, Seguin SJ, Ganassi M, Bigi I, Diacci C, Zelotti E, Baratashvili M, Gregory JM, et al. (2016). The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity. Human Molecular Genetetics 25:3908–3924. https://doi.org/10.1093/hmg/ddw232
  57. ↑ Mehta AR, Walters R, Waldron FM, Pal S, Selvaraj BT, Macleod MR, Hardingham GE, Chandran S, Gregory JM. (2019). Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Communications 1:fcz009. https://doi.org/10.1093/braincomms/fcz009
  58. ↑ Gregory JM, Livesey MR, McDade K, Selvaraj BT, Barton SK, Chandran S, Smith C. (2020). Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain. Journal of Pathology 250:67–78. https://doi.org/10.1002/path.5351
  59. ↑ Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, Story D, McDade K, Smith C, Morton NM, et al. (2021). Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropatholica 141:257–279. https://doi.org/10.1007/s00401-020-02252-5
  60. ↑ Waldron FM, Gregory JM. (2024). An adaptable protocol for antibody & TDP-43 RNA aptamer dual immunohistochemical staining for FFPE-preserved human tissue: with SOP and tick-sheet. https://www.protocols.io/view/an-adaptable-protocol-for-antibody-amp-tdp-43-rna-yxmvm97k6l3p/v1
  61. ↑ Waldron FM, Rifai OM, Gregory JM. (2024). Antibody and TDP-43 RNA aptamer dual staining to detect patterns of co-pathology in FFPE-preserved human tissue: A SOP and tick-sheet. https://www.protocols.io/view/antibody-and-tdp-43-rna-aptamer-dual-staining-to-d-14egn6wnml5d/v1
  62. ↑ Waldron FM, Spence H, Gregory JM. (2024). TDP-43 RNA aptamer staining to detect pathological TDP-43 in FFPE human tissue: A SOP and tick-sheet. https://www.protocols.io/view/tdp-43-rna-aptamer-staining-to-detect-pathological-eq2lyjo4mlx9/v2
  63. ↑ Target ALS Basic Biology (Consortium) Grant: “Probing RNA-binding protein aggregates at the nanoscale using in-silico-designed aptamers”. https://www.targetals.org/2025/03/04/basicbiology/
  64. ↑ Interview with Jenna Gregory, Ph.D., 2023 Target ALS Annual Meeting. https://www.youtube.com/watch?v=69OI3LX39pA&t=5s
  65. ↑ MND Association. Mapping TDP-43 and FUS pathology across motor control networks. https://www.mndassociation.org/research/our-research/research-we-fund/understanding-clinical-progression/mapping-patterns-tdp-43
  66. ↑ NIH RO1: “The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal Dementia”. https://reporter.nih.gov/search/MgJvoeXFHU6eUacDJu0iMg/project-details/10896182#details
  67. ↑ MND Scotland funded project to explore crucial aspect of MND. https://mndscotland.org.uk/news/mnd-scotland-funded-project-to-explore-crucial-aspect-of-neurodegenerative-diseases/
  68. ↑ Scottish Universities Life Sciences Alliance (SULSA) Postdoctoral and Early Career Researcher Exchange Scheme (PECRE) Award. https://sulsa.ac.uk/postdoc-exchanges/
  69. ↑ UKRI/MRC (2023). NanoString Integrated Spatial Biology Platform. https://gtr.ukri.org/projects?ref=MC_PC_MR%2FY002725%2F1
  70. ↑ CSO (2024). Scottish Government’s Chief Scientist Office Clinical Academic Fellowship. https://www.cso.scot.nhs.uk/funded-research/fellowships/caf/
  71. ↑ MND Scotland. Clinical Academic Fellowship Announced for MND Research. https://mndscotland.org.uk/news/clinical-academic-fellowship-announced-for-mnd-research/
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.